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Excellence (NICE) guidelines. Multivariable logistic regression was performed to 
examine the association between non-indication based PPI use and various patient 
and physician-level characteristics using 2008-2010 NAMCS data. RESULTS: The 
use of PPIs increased from 5.29% patient visits in 2002 to 11.82% in 2010 (p< .0001). 
Prescription of PPI without an appropriate indication by primary care physicians 
(54.26% to 48.84%), medical specialists (35.21% to 35.62%) and surgeons (10.52% 
to 15.53%) did not change significantly between 2005-2010 (p= 0.55). Additionally, 
80.12% of patient visits involved PPI prescriptions without an appropriate indi-
cation. Results of multivariable logistic regression revealed that, patients with 
more than 3 chronic conditions were significantly more likely to be prescribed 
a PPI without an appropriate indication as compared to patient visits without 
a chronic condition (Odds Ratio (OR) = 2.49, 95% Confidence Interval (CI): 1.26-
4.94). CONCLUSIONS: PPI use among the elderly increased significantly over the 
study period, with 8 out of 10 patient visits involving PPI prescriptions without an 
appropriate indication. Additionally, the study found no change in PPI prescribing 
trend across physician specialties. These findings suggest the need to improve 
quality of PPI prescribing in the vulnerable elderly population.
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OBJECTIVES: to estimate the tangible savings generated when there is a joint 
effort between Pharmacist and Physician METHODS: observational descriptive 
study. Population: patient records belonging to an IPS Bogota, diagnosed with 
Osteoporosis in parenteral drug therapy with bisphosphonates (Zoledronic Acid 
5mg Ibandronic Acid 3mg). Observation period: June 2012 to June 2013 (n= 161). The 
Pharmacist identified patients with non-pertinence to parenteral bisphosphonate. 
Non-pertinence was defined when: the patients had osteopenia (no additional risk 
factors), had renal function < 35 ml/min, no previous scaling with oral medications 
and when were men with diagnosis of osteoporosis. Finally, the Physician defined 
the behavior to follow (changing drug therapy). Analysis: were used absolute and 
relative frequencies, measures central tendency and dispersion. Treatment direct 
costs were quantified before and after assessment by the Pharmacist and the 
Physician. The statistical software SPSS 21 license under the CES University was 
used. RESULTS: pharmacist non-pertinence identified in 34% (54/161) of patients, 
of which, the Physician agreed in 70% of cases (38/54). The 39% of patients switched 
to oral bisphosphonates (Calcium Alendronate 70mg, Strontium Ranelate 2mg, 
Risedronate 35mg), 40% Calcium and Vitamin D3 and 21% left without medication. 
Given that patients were pretreated with Zoledronic Acid 5mg (25/38) or Ibandronic 
Acid 3mg (13/38), this conduct involved a decreased 18% a year later, with savings/
year $ 9,164 (considering only the value of the drugs). CONCLUSIONS: the joint 
work between Pharmacist and Physician showed an important saving in rational 
use of medicines.
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OBJECTIVES: To estimate the incidence of polypharmacy and its strength of asso-
ciation with respect to medication regimen among patients (pediatric and adults) 
visiting ED of a tertiary care hospital in Karachi Pakistan. METHODS: Retrospective 
data was collected of all patients, who visited the Emergency Department (ED) of 
Aga Khan University Hospital, Karachi (AKUH) during January, 2012 to December, 
2012. The detailed clinical records on medication prescribing from admission 
through discharge of all patients was reviewed. RESULTS: Total 51,000 patients 
visited ED during January 2012 till December 2012, out of those polypharmacy 
was common in 40% of patients. Male were 56.6%(9,837) while 43.4% (7,553) were 
females. Peadiatric patients were 17.9% (3,145) while 79% (14,279) were adults. The 
most common triage category for patients was P3 with 37.2% (6,483). Most of these 
patients were those who were recommended admission in other wards 59.6% 
(10,146), 26.5% (4,514) discharged patients and 9% (1,536) leave against medical 
advice (LAMA) patients. CONCLUSIONS: The perils and problems associated with 
Poly pharmacy are a subject of interest as polypharmacy was significant finding 
among all ED patients. The results from this study serves as a baseline to iden-
tifying the drug- related problems among EP and could helpful for pharmacists 
and physicians to develop and implement strategy for risk management in ter-
tiary care hospital. keywords: Polypharmacy, Emergency Department, Emergency 
patients.
PHS107
Prevalence and determInantS of low-coSt generIc drug Program 
uSe In tHe PrIvately-InSured adult PoPulatIon
Pauly N., Brown J.
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Low-cost generic drug programs (LCGPs) offer an affordable way for 
individuals to obtain a wide variety of prescription drugs, but they may lead to 
exposure misclassification in administrative claims datasets. This study sought to 
assess the prevalence and determinants of LCGP use in a privately-insured adult 
population. METHODS: This study relied on data from the Medical Expenditure 
Panel Survey from 2005 – 2011. LCGP use was defined by two stipulations 1) The 
total cost of the drug was paid out of pocket and 2) The cost of the drug exactly 
matched the cost of an LCGP program. Demographics of LCGP users and non-
users were compared. A multivariable logistic model was estimated to identify 
the determinant variables associated with LCGP use. RESULTS: Of the total study 
among the youngest societies in the developed world. Further efforts are required 
to reduce the substantial CHF burden.
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OBJECTIVES: U.S. healthcare spending on high-cost biologics has escalated over the 
past decade. The Biologics Price Competition and Innovation Act allows for biosimi-
lar products in the United States, which will be lower-cost alternatives to reference 
biologics. This study explored payer attitudes to the reimbursement and adoption 
of biosimilars in the United States. METHODS: Some 61 U.S. medical or phar-
macy directors at managed care organizations (MCOs) were surveyed during 2014 
regarding their expectations for biosimilar reimbursement. RESULTS: Respondents 
indicate that MCOs expect biosimilars to offer a significant discount to the refer-
ence brand to secure reimbursement. A mean discount of 23-24% is considered 
adequate for reimbursement, while 33-34% is deemed necessary for preferential 
reimbursement to the reference brand. Rapid formulary inclusion of biosimilars is 
expected, with 79% of respondents indicating formulary inclusion within 12 months 
of launch. Widespread reimbursement of biosimilars in extrapolated indications is, 
however, uncertain, with only 34% of respondents reporting that their MCO would 
unconditionally reimburse a biosimilar under such circumstances. Payers expect 
to employ various strategies to promote biosimilar uptake, from favorable tiering 
to step-therapy requiring biosimilar prescribing prior to the reference brand. The 
most conducive uptake strategies are expected for products with deep discounts. 
In addition, payers will run educational campaigns for physicians. However, ≥ 80% 
of respondents say their biosimilar approach will likely be influenced by thought-
leading physicians and medical associations. Furthermore, widespread “grandfa-
thering” is expected, i.e. continuation of the reference brand in responsive/stable 
patients. CONCLUSIONS: U.S. payers will preferentially promote biosimilars over 
reference brands using various demand- and supply-side measures, so long as bio-
similars meet their discount expectations and have clinical stakeholder buy-in. 
Payers clearly seek to realize the cost savings biosimilars offer; however, tendency 
to seek clinical stakeholder buy-in, coupled with likelihood of extensive “grand-
fathering”, indicates some need for more robust evidence of cost-effectiveness.
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OBJECTIVES: Medical specialists have an essential role in promotion of generic 
medicines. However, misconceptions and negative perceptions about generic medi-
cines among them could be a major barrier to utilization of generic medicines. 
Therefore, the aim of this study was to explore their knowledge, perceptions and 
views about generic medicines. METHODS: A qualitative methodology was adopted 
in this study. A qualitative descriptive (QD) study with phenomenology overtones 
was the research strategy. Face-to-face semi-structured interviews were conducted 
with a purposive sample of medical specialists until saturation of data was achieved. 
The interviews were audio taped and transcribed verbatim. Then, the subsequent 
transcripts were analysed using thematic analysis. The themes were generated 
using both deductive (theoretical) and inductive coding. To ensure reliability of data 
analysis, peer review and independent analysis of the data was done. RESULTS: Five 
major themes were identified: (1) factors affecting specialists’ prescribing practice 
with regards to generic medicines and original brand medicines, (2) specialists’ per-
ceptions of efficacy, safety and quality of generic medicines, (3) specialists’ knowl-
edge and confidence with Malaysian generic regulatory approval system, (4) drug 
information sources used by the specialists and (5) international non-proprietary 
name (INN) prescribing. CONCLUSIONS: The study findings showed that several 
factors influenced prescribing decision with regards to the brands of the medicines 
including familiarity and experience with generic medicines, medical and clinical 
condition of the patient, availability of the medicine brand in the hospital and 
department financial allocations. Moreover, misconceptions about quality, safety, 
efficacy and bioequivalence of generic medicines were prevalent among the partici-
pants. Furthermore, the participants were not familiar with the Malaysian generic 
medicines approval system. Therefore, medical specialists’ concerns need to be 
addressed. Some recommendations and suggestions were made to improve generic 
medicines utilization in the country.
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OBJECTIVES: The study aimed to examine the utilization patterns of Proton Pump 
Inhibitors (PPIs) among the elderly and the trends in PPI prescribing across phy-
sician specialties in US office-based settings. The study also evaluated various 
patient and physician-level factors affecting non-indication based PPI prescrip-
tion in the above population. METHODS: This retrospective cross-sectional study 
used 2002-2010 National Ambulatory Medical Care Survey (NAMCS) and outpa-
tient portion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) 
data to evaluate PPI utilization patterns based on patient visits. PPI prescribing 
trend among different physician specialties was estimated using 2005-2010 
NAMCS data. Evidence-based indications for PPIs included the US Food and Drug 
Administration (FDA) approved indications and the National Institute of Clinical 
